OakChart

Whitehawk Therapeutics Inc

WHWKHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 2:26 PM ET

3.12+0.04 (1.25%)
2026-11-11 20:27 CET
Market cap
- USD m
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
-73.65 USD m
EPS diluted, TTM
-
P/E
-
Compare

Price

WHWK against its 20, 50 and 200-day averages
2050200beatmiss
3.004.005.002.6M5.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26WHWKclose 3.1220-day 3.1750-day 3.60200-day 3.853.1252w high

43.3% under the 52-week high of 5.50 on 14 May 2026. 52-week low 1.97 on 20 Nov 2025. Last 15 sessions, 20.6% high to low

Profile

WHWK
52-week range, 33% of the way up
1.975.49

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

IndexRUT
Employees23
IPOAug 08, 2017
Beta0.97
ATR, 14d0.21
Rel volume0.62
Short float7.57%
Insider own42.36%
Inst own59.18%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap184.02M
Enterprise Value14.57M
Income-83.29M
Sales0.00M
Book/sh2.76
Cash/sh2.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees23
IPOAug 08, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.13
P/C1.08
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.47
Current Ratio16.47
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.08
EPS next Y-0.91
EPS next Q-0.22
EPS this Y-184.85%
EPS next Y2.74%
EPS next 5Y-
EPS past 3/5Y50.16% 58.28%
Sales past 3/5Y-22.27% -13.29%
EPS Y/Y TTM-825.52%
Sales Y/Y TTM-100.00%
EPS Q/Q11.86%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.-7.33% -

Ownership

Insider Own42.36%
Insider Trans0.00%
Inst Own59.18%
Inst Trans10.35%
ROA-48.90%
ROE-52.01%
ROIC-51.02%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-1.47%
SMA50-13.27%
SMA200-19.03%
Trades-

Technical

Shs Outstand59.01M
Shs Float32.86M
Short Float7.57%
Short Ratio7.17
Short Interest2.49M
52W High5.49 -43.25%
52W Low1.97 58.30%
Volatility6.95% 6.83%
ATR (14)0.21
RSI (14)43.17
Beta0.97
Rel Volume0.62
Avg Volume346.88K
Volume166,940

Performance

Perf Week-1.62%
Perf Month3.26%
Perf Quarter-33.37%
Perf Half Y-36.74%
Perf YTD28.86%
Perf Year39.84%
Perf 3Y-32.06%
Perf 5Y-85.68%
Perf 10Y-
Recom1.57
Target Price7.33
Prev Close3.08
Price3.12
Change %1.25%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 01, 2026InitiatedSStifelBuy$9+188.6%
Jul 13, 2026InitiatedLLeerink PartnersOutperform$9+188.6%
Jun 25, 2026InitiatedRB. Riley SecuritiesBuy$10+220.7%
Feb 05, 2026InitiatedOOppenheimerOutperform$6+92.4%
Aug 27, 2024DowngradePPiper SandlerOverweight → Neutral$5 → $1.75-43.9%
Aug 21, 2024DowngradeTTD CowenBuy → Hold
Aug 21, 2024DowngradeJJefferiesBuy → Hold$11 → $1.50-51.9%
Dec 15, 2023DowngradeHH.C. WainwrightBuy → Neutral
Jan 11, 2022InitiatedJJefferiesBuy$45+1,343.0%
Oct 01, 2021InitiatedCCowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
PYXSPyxis Oncology Inc194.36M
MGNXMacrogenics Inc153.83M
STROSutro Biopharma Inc170.21M
CTMXCytomX Therapeutics Inc466.84M
VRXAVeraxa Biotech AG186.14M
IMNMImmunome Inc2.27B
ZYMEZymeworks BC Inc2.02B
BOLTBolt Biotherapeutics Inc12.04M
CMPXCompass Therapeutics Inc149.34M
ANLAdlai Nortye Group Ltd ADR641.06M

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Giacobello Scott M.CHIEF FINANCIAL OFFICERApr 16 '26Sale4.13141,600584,808295,224Apr 17 04:53 PM
Giacobello Scott M.CHIEF FINANCIAL OFFICERApr 15 '26Sale3.8677,000297,220436,824Apr 17 04:53 PM
Giacobello Scott M.OfficerApr 15 '26Proposed Sale3.85233,766899,999Apr 15 08:03 PM
BALL BRYANSee remarksApr 14 '26Sale3.6492,460336,554397,106Apr 15 07:59 PM
BALL BRYANSee remarksApr 13 '26Sale3.4626,38991,306489,566Apr 15 07:59 PM
BALL BRYANSee remarksApr 09 '26Sale3.5750,000178,500522,551Apr 13 08:34 PM
BALL BRYANSee remarksApr 10 '26Sale3.436,59622,624515,955Apr 13 08:34 PM
Lennon David JamesCHIEF EXECUTIVE OFFICERApr 09 '26Sale3.3814,50049,010518,622Apr 10 06:46 PM
BALL BRYANOfficerApr 09 '26Proposed Sale3.30196,969649,998Apr 09 08:38 PM
Lennon David JamesOfficerApr 09 '26Proposed Sale3.384,36414,750Apr 09 07:54 PM
Lennon David JamesCHIEF EXECUTIVE OFFICERApr 06 '26Sale3.51102,395359,406691,154Apr 08 08:32 PM
Lennon David JamesCHIEF EXECUTIVE OFFICERApr 07 '26Sale3.4394,087322,718597,067Apr 08 08:32 PM
Lennon David JamesCHIEF EXECUTIVE OFFICERApr 08 '26Sale3.4063,945217,413533,122Apr 08 08:32 PM
Lennon David JamesCHIEF EXECUTIVE OFFICERApr 02 '26Sale3.4826,85893,466793,549Apr 03 06:17 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
OASCOneAscent Enhanced Small and Mid Cap ETFAUM: 100.50M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

News

latest 14 of 200
  • Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights (PR Newswire)
  • Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 (PR Newswire)
  • Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 (PR Newswire)
  • Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors (PR Newswire)
  • Whitehawk Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
  • Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights (PR Newswire) +15.48%
  • Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development (Business Wire)
  • Whitehawk Therapeutics Presents Real-World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 (PR Newswire)
  • Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference (PR Newswire)
  • WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise (Stocktwits)
  • Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload (PR Newswire)
  • Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit (PR Newswire)
  • Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum (PR Newswire) -7.84%
  • Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing (PR Newswire) +25.77%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.230-0.214-0.2300.000.007
2026Q22026-08-06-0.200-0.296-0.2010.00-0.357
2026Q12026-05-07-0.320-0.358-0.3210.000.004
2025Q42026-03-12-0.340-0.483-0.3360.000.004
2025Q32025-11-06-0.2600.067-0.2560.000.003
2025Q22025-08-07-0.7600.825-0.7620.0050.002
2025Q12025-05-081.830-0.4601.8297.150.003
2024Q42025-03-18-0.670-0.295-0.6757.247.442
2024Q32024-11-06-0.460-0.458-0.4647.216.594
2024Q22024-08-07-0.540-0.690-0.5406.186.195
2024Q12024-05-08-0.680-0.624-0.6785.356.475
2023Q42024-03-13-0.600-0.648-0.6036.336.295
2023Q32023-11-08-0.600-0.724-0.6055.966.625
2023Q22023-08-09-0.670-0.622-0.6696.206.205
2023Q12023-05-10-0.570-0.584-0.5675.875.485
2022Q42023-03-28-0.520-0.668-0.5185.234.824

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-096000.000.000.00
2026Q4S2026-10-206000.000.000.00
2026Q4S2026-10-016100.000.000.00
2026Q4S2026-09-297100.000.000.00
2026Q4S2026-08-066100.000.000.00
2026Q4S2026-07-29600-0.77-4.600.00
2026Q4S2026-07-10700-0.66-4.600.00
2026Q4S2026-06-236000.000.000.00
2026Q4S2026-05-135000.000.000.00
2026Q4S2026-05-074000.000.000.00
2026Q4S2026-04-154000.000.000.00
2026Q4S2026-03-293000.000.000.00
2026Q4S2026-03-194000.000.000.00
2026Q4S2026-03-123000.000.000.00

Estimate history

EPS, annual-15.45-4.596-8.6-26.344-12.41-2.688-2.443-2.356-0.333-1.0832
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.464-0.6751.829-0.762-0.256-0.336-0.321-0.201-0.226
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual020.157014.581.1215.21624.35425.9837.1450
Period201720182019202020212022202320242025TTM
Sales, quarterly7.2127.2397.145000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.8052.7062.7060.16920.89524.43524.55424.68147.14659.009
Period201720182019202020212022202320242025MRQ
Shares, quarterly24.61524.68146.78547.12847.12847.14647.19757.00959.009
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

No statement data.

Income statement, quarterly

No statement data.

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments145.7047.24108.84172.56148.994.4638.5262.6120.26
Short Term Receivables0.005.905.491.860.0014.150.000.000.00
Inventories0.005.316.431.860.000.000.000.000.00
Other Current Assets3.322.843.833.752.280.081.051.370.64
Total Current Assets149.0161.29124.59180.03151.2718.6839.5763.9820.90
Net Property, Plant & Equipment0.007.635.972.030.610.140.330.100.11
Total Investments and Advances0.000.060.060.060.000.000.000.000.00
Intangible Assets---0.003.810.000.000.000.00
Deferred Tax Assets0.120.39-------
Other Assets1.811.331.802.112.210.000.040.040.02
Total Assets150.9470.71132.42184.24157.9118.8239.9464.1221.03
Short Term Debt Incl. Current Port. of LT Debt0.000.276.190.390.3923.470.100.000.00
Accounts Payable0.922.165.903.526.442.390.440.600.00
Other Current Liabilities13.6014.6514.3114.928.454.202.794.863.59
Total Current Liabilities14.5217.0726.3918.8415.2730.063.335.463.59
Long Term Debt0.000.560.837.026.231.100.070.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.120.39-------
Other Liabilities0.000.200.000.000.000.100.000.000.00
Total Liabilities14.6318.2327.2325.8621.5031.263.405.463.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity136.3152.48105.19158.38136.41-12.4336.5458.6717.44
Total Shareholders Equity136.3152.48105.19158.38136.41-12.4336.5458.6717.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity136.3152.48105.19158.38136.41-12.4336.5458.6717.44
Total Liabilities & Stockholders Equity150.9470.71132.42184.24157.9118.8239.9464.1221.03
Book Value Per Share2.892.134.286.486.53-73.3613.5021.689.66
Tangible Book Value Per Share2.892.134.286.486.35-73.3613.5021.689.66
Full-Time Employees234089793912122725
Price to Book Ratio1.111.130.421.853.701.080.691.185.49
Return on Assets-18.58-62.71-41.54-35.37-108.55-11.84-44.73-24.42-182.72
Return on Equity-21.82-80.79-49.90-41.06-122.69-28.86-48.89-27.32-860.37
Return on Invested Capital-15.11-120.07-62.03-36.59-77.18--63.58-17.72-122.74
Quick Ratio10.263.284.489.469.900.6211.8711.735.82
Current Ratio10.263.594.729.569.900.6211.8711.735.82

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-83.29-20.60-63.69-65.77-60.51-110.09-3.48-23.27-10.40
Depreciation0.000.080.190.170.160.280.180.080.05
Other Funds (Non Cash)5.99-78.8510.009.3412.5375.151.111.233.43
Funds from Operations-77.31-99.36-53.50-56.26-47.82-34.67-2.19-21.96-6.92
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.661.93-6.05-3.40-1.8212.24-10.51-1.891.11
Cash from Operating Activities-73.64-97.43-59.55-59.66-49.64-22.42-12.70-23.85-5.81
Capital Expenditures-0.00-0.55-1.65-3.97-0.44-0.050.00-0.24-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.00101.290.000.000.0029.700.000.00-
Purchase or Sale of Investments23.02-88.8426.8687.18-132.440.000.000.000.00
Purchase of Investments-128.33-148.69-36.48-64.44-145.190.000.000.000.00
Sale Or Maturity of Investments151.3559.8463.34151.6212.750.000.000.000.00
Other Uses0.000.000.000.000.00-4.500.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities23.0211.8925.2083.21-132.8925.150.00-0.24-0.04
Cash Dividends Paid0.000.000.000.000.00-4.410.000.000.00
Change in Capital Stock87.30100.000.130.3372.62146.220.000.0051.70
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock87.30100.000.130.3372.62146.220.000.0051.70
Proceedsfrom Stock Options-0.26-0.03-0.020.2572.16145.380.000.0051.62
Issuance or Reduction of Debt, Net0.000.000.000.000.000.001.190.000.00
Change in Long Term Debt0.000.000.000.000.000.001.190.000.00
Issuance of Long Term Debt0.000.000.000.000.000.001.190.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-5.62-5.620.000.000.000.000.000.00-3.50
Other Financing Activities Uses-5.62-5.620.000.000.000.000.000.00-3.50
Cash from Financing Activities81.6794.380.130.3372.62141.801.190.0048.20
Net Change in Cash31.048.83-34.2223.87-109.91144.53-11.51-24.0942.35
Free Cash Flow-73.65-97.98-61.20-63.63-50.08-22.47-12.70-24.09-5.85
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments169.67189.98123.04145.70162.60177.20
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.302.432.503.322.441.47
Total Current Assets171.97192.41125.55149.01165.04178.67
Net Property, Plant & Equipment0.210.000.000.000.000.01
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---0.12--
Other Assets1.501.581.681.811.982.14
Total Assets173.69193.99127.23150.94167.02180.82
Short Term Debt Incl. Current Port. of LT Debt0.130.000.000.000.000.00
Accounts Payable2.221.101.750.921.633.34
Other Current Liabilities8.099.969.3113.608.225.42
Total Current Liabilities10.4411.0711.0614.529.858.76
Long Term Debt0.090.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.12--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.5311.0711.0614.639.858.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity163.16182.93116.17136.31157.17172.07
Total Shareholders Equity163.16182.93116.17136.31157.17172.07
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity163.16182.93116.17136.31157.17172.07
Total Liabilities & Stockholders Equity173.69193.99127.23150.94167.02180.82
Book Value Per Share2.763.212.462.893.333.65
Tangible Book Value Per Share2.763.212.462.893.333.65
Full-Time Employees37--23--
Price to Book Ratio1.111.861.190.730.520.39
Return on Assets-48.90-42.60-64.12-18.58-12.36-7.38
Return on Equity-52.01-44.98-68.54-21.82-13.82-8.31
Return on Invested Capital-12.99-9.10-19.10-17.06-11.29-30.58
Quick Ratio16.4717.3811.3610.2616.7620.41
Current Ratio16.4717.3811.3610.2616.7620.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.21-16.64-22.19-23.25-17.75-52.62
Depreciation0.000.000.000.000.010.02
Other Funds (Non Cash)1.421.161.851.562.183.09
Funds from Operations-19.79-15.48-20.35-21.69-15.56-49.51
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.120.95-1.864.460.18-3.45
Cash from Operating Activities-19.67-14.53-22.21-17.23-15.38-52.96
Capital Expenditures-0.000.000.000.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00-0.070.00
Purchase or Sale of Investments3.61-16.8719.4316.85-91.56-28.82
Purchase of Investments-35.59-50.63-19.19-22.92-93.56-32.22
Sale Or Maturity of Investments39.2033.7738.6239.762.003.39
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities3.61-16.8719.4316.85-91.63-28.83
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.1981.840.005.650.00-0.85
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.1981.840.005.650.00-0.85
Proceedsfrom Stock Options-0.19-5.720.005.650.00-0.85
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-5.620.000.00
Other Financing Activities Uses0.000.000.00-5.620.000.00
Cash from Financing Activities-0.1981.840.000.030.00-0.85
Net Change in Cash-16.2650.44-2.78-0.36-107.00-82.63
Free Cash Flow-19.68-14.53-22.21-17.23-15.38-52.96

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 25.98M 2025: 7.15M
United States2024: 25.98M 2025: 7.15M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.57%2.5M32.9M346.00K
2026-10-157.97%2.6M32.9M366.72K
2026-09-308.25%2.7M32.9M398.83K
2026-09-158.75%2.7M31.2M470.07K
2026-08-319.57%3.0M31.2M453.97K
2026-08-1416.15%5.0M31.2M471.82K
2026-07-3112.81%4.4M34.6M502.70K
2026-07-1512.81%4.2M32.6M465.33K
2026-06-308.69%2.8M32.6M407.83K
2026-06-153.62%1.2M32.6M300.56K
2026-05-292.81%0.8M30.0M306.52K
2026-05-152.85%0.9M30.0M269.91K
2026-04-302.69%0.8M30.6M184.33K
2026-04-152.76%0.8M28.3M163.10K
2026-03-312.64%0.7M26.2M148.26K
2026-03-132.75%0.7M26.2M144.28K
2026-02-272.98%0.8M26.2M135.83K
2026-02-132.97%0.8M26.2M149.70K
2026-01-303.23%0.8M26.2M162.47K
2026-01-152.98%0.8M26.2M1.77M

Option chain

expiry -
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

0
FiledFormDescriptionPeriodLink
No filings.

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-04002.55M11
2026-030031.53K3
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Yu Fan9.04%
ACUTA CAPITAL PARTNERS, LLC8.71%
QVT Financial LP8.58%
MONTANOVA CAPITAL, LLC8.00%
ORBIMED ADVISORS LLC7.32%
Avoro Capital Advisors LLC5.30%
Siren, L.L.C.4.35%
KVP Capital Advisors, LP4.03%
BlackRock, Inc.3.58%
VANGUARD CAPITAL MANAGEMENT LLC2.58%

Funds

Fund% owned
Avantis Emerging Markets Equity ETF22.23%
First Trust Emerging Markets AlphaDEX Fund21.39%
Vident International Equity Strategy ETF7.67%
JNL Multi-Manager International Small Cap Fund7.64%
WisdomTree Emerging Markets ex-State-Owned Enterprises Fund4.13%
Avantis Emerging Markets Value ETF2.36%
iShares Russell 2000 ETF1.36%
Avantis Emerging Markets Equity Fund0.84%
Fidelity Small Cap Index Fund0.65%
Avantis Emerging Markets ex-China Equity ETF0.55%

OakChart. WHWK. Cached 15 minutes.

Some panels did not load: fc, oc, lf, dv.